Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

PHASE1CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

April 22, 2019

Primary Completion Date

February 25, 2020

Study Completion Date

February 25, 2020

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

MGTA-145

MGTA-145 will be given in various doses intravenously

BIOLOGICAL

plerixafor

240 µg/kg subcutaneously

BIOLOGICAL

Placebo

Placebo will be given in various doses intravenously

Trial Locations (1)

Medpace CPU, Cincinnati